Galvin, Gaustad & Stein, LLC Vertex Pharmaceuticals Inc Transaction History
Galvin, Gaustad & Stein, LLC
- $1.02 Billion
- Q2 2024
A detailed history of Galvin, Gaustad & Stein, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Galvin, Gaustad & Stein, LLC holds 36,685 shares of VRTX stock, worth $17.5 Million. This represents 1.68% of its overall portfolio holdings.
Number of Shares
36,685
Previous 27,405
33.86%
Holding current value
$17.5 Million
Previous $11.5 Million
50.1%
% of portfolio
1.68%
Previous 1.11%
Shares
3 transactions
Others Institutions Holding VRTX
# of Institutions
1,717Shares Held
226MCall Options Held
1.21MPut Options Held
1.56M-
Capital World Investors Los Angeles, CA26.7MShares$12.7 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$10.9 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.1 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.58 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$4.06 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $122B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...